Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...
Hosted on MSN2d
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD
High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.
Cumberland reports progress in DMD heart disease trial
NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...
Nashville Post3d
Cumberland Pharmaceuticals stock climbs
Cumberland Pharmaceuticals saw its shares pop almost 34 percent on heavy volume Tuesday following positive results from a ...
FierceBiotech3d
Cumberland's Duchenne drug improves blood flow from heart in phase 2 trial
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...
Cumberland reports ‘positive’ results from Phase 2 FIGHT DMD trial
Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel ...
Cumberland Vaults on DMD Test Results
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares began Tuesday sharply higher. Cumberland, a specialty pharmaceutical company with development efforts focused on new products for rare diseases, ...
BioWorld4d
DMD space takes heart from Cumberland’s phase II ifetroban data
The first successful phase II trial in Duchenne muscular dystrophy (DMD) heart disease rolled out from Cumberland Pharmaceuticals Inc., which said top-line findings from the experiment called Fight ...